Spotlight On Promising Penny Stocks In July 2025
Top 10 Penny Stocks In The United States
Name
Share Price
Market Cap
Financial Health Rating
ATRenew (RERE)
$3.37
$810.62M
★★★★★★
Waterdrop (WDH)
$1.98
$658.23M
★★★★★★
CuriosityStream (CURI)
$4.55
$268.34M
★★★★★★
WM Technology (MAPS)
$0.951
$164.19M
★★★★★★
Perfect (PERF)
$2.48
$259.71M
★★★★★★
Tuniu (TOUR)
$0.9326
$100.75M
★★★★★★
Cardno (COLD.F)
$0.1701
$6.64M
★★★★★★
BAB (BABB)
$0.886
$6.1M
★★★★★★
Lifetime Brands (LCUT)
$4.72
$109.16M
★★★★★☆
Tandy Leather Factory (TLF)
$3.47
$29.28M
★★★★★★
Click here to see the full list of 412 stocks from our US Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
PetMed Express
Simply Wall St Financial Health Rating: ★★★★★★
Overview: PetMed Express, Inc., along with its subsidiaries, operates as a pet pharmacy in the United States and has a market cap of approximately $77.56 million.
Operations: The company generates revenue through its online retail operations, amounting to $247.01 million.
Market Cap: $77.56M
PetMed Express, Inc. operates with a market cap of US$77.56 million and generates revenue of US$247.01 million through its online pet pharmacy services. Despite becoming profitable recently, the company faces challenges including a large one-off loss impacting recent financial results and an inexperienced board and management team with average tenures of 2.2 and 1.1 years, respectively. The company's short-term assets exceed both its short- and long-term liabilities, indicating solid liquidity despite no debt concerns. Recent delays in SEC filings have led to Nasdaq compliance issues but do not currently affect trading activities or stock listing status.
Dive into the specifics of PetMed Express here with our thorough balance sheet health report.
Learn about PetMed Express' future growth trajectory here.
Mega Matrix
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Mega Matrix Inc. operates a streaming platform called FlexTV, specializing in vertical screen entertainment, with a market cap of $107.33 million.
Operations: The company's revenue is primarily derived from the Asia-Pacific region ($17.26 million), followed by the United States and Canada ($11.66 million), Europe, Middle East and Africa ($4.54 million), and Latin America ($1.76 million).
Market Cap: $107.33M
Mega Matrix Inc., with a market cap of US$107.33 million, operates FlexTV, focusing on vertical screen entertainment. The company is unprofitable but maintains a strong cash runway exceeding three years and has no debt. Its recent strategic alliance with Wardour Studios to form AIFLIX LLC aims to leverage AI for short drama production, potentially enhancing its content offerings and global reach. Despite increased volatility and declining sales from US$8.69 million to US$7.74 million year-over-year, the appointment of seasoned investor Yaman Demir as an executive director may bolster its strategic direction in digital assets and innovation initiatives.
Click here to discover the nuances of Mega Matrix with our detailed analytical financial health report.
Evaluate Mega Matrix's historical performance by accessing our past performance report.
Tilly's
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Tilly's, Inc. is a specialty retailer in the United States offering casual apparel, footwear, accessories, and hardgoods for young men and women as well as boys and girls, with a market cap of $49.15 million.
Operations: The company generates revenue from its retail segment focused on apparel, totaling $561.21 million.
Market Cap: $49.15M
Tilly's, Inc., with a market cap of US$49.15 million, has faced challenges as evidenced by its removal from multiple Russell indices. Despite generating US$561.21 million in revenue from its retail segment, the company remains unprofitable with losses increasing over the past five years. Its short-term assets of US$127 million exceed short-term liabilities but fall short of covering long-term liabilities of US$138.5 million. The management and board are experienced, averaging over 10 years tenure each, while the company benefits from being debt-free and trading at good value compared to peers despite high volatility and negative return on equity.
Take a closer look at Tilly's potential here in our financial health report.
Examine Tilly's earnings growth report to understand how analysts expect it to perform.
Seize The Opportunity
Click here to access our complete index of 412 US Penny Stocks.
Want To Explore Some Alternatives? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PETS MPU and TLYS.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
CONMED (CNMD) Q2 Earnings: What To Expect
Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Packaged foods company Kraft Heinz (NASDAQ:KHC) will be reporting results this Wednesday before market open. Here's what investors should know. Kraft Heinz met analysts' revenue expectations last quarter, reporting revenues of $6.00 billion, down 6.4% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' EBITDA estimates but full-year EPS guidance missing analysts' expectations. Is Kraft Heinz a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Kraft Heinz's revenue to decline 3.1% year on year to $6.27 billion, in line with the 3.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.64 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 10 analysts). Looking at Kraft Heinz's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lamb Weston delivered year-on-year revenue growth of 4%, beating analysts' expectations by 5.7%, and McCormick reported flat revenue, in line with consensus estimates. Lamb Weston traded up 19.3% following the results while McCormick was also up 3.6%. Read our full analysis of Lamb Weston's results here and McCormick's results here. There has been positive sentiment among investors in the shelf-stable food segment, with share prices up 3.8% on average over the last month. Kraft Heinz is up 9.3% during the same time and is heading into earnings with an average analyst price target of $30.18 (compared to the current share price of $28.22). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
